| Name | Title | Contact Details |
|---|---|---|
Bala Krishnapillai |
Chief Information Officer, Hitachi Americas | Profile |
Welcome to Hollywood Chrysler Jeep! Here at Hollywood Chrysler Jeep, we pride ourselves on taking a different approach to selling vehicles by getting to know each and every one of our customers so we can provide a comfortable and unique shopping atmosphere. To us, its about so much more than just making the sale, because we know how important getting a fair deal on quality transportation really is for you!
We believe that every brand has a unique story waiting to be told. Founded with a strong commitment to diversity and guided by a dynamic women-led culture, T Palmer Agency is here as your partner to help you build and tell your story. Bringing creativity and innovation to the forefront, we go beyond traditional brand and event strategy to streamline and create impactful messaging, and relationships and curate experiences that leave a lasting imprint. New York & Las Vegas.
Inspectis Digital Microscopes are elegant solutions for modern optical inspection tasks. We manufacture carefully specified Optical Systems for optimum performance, sleekly designed and made from durable high quality materials making them fit for purpose of a long life in real working environments.
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.